Search Results
Your search for can matches 13751 pages
Showing 2001 - 2050New Study Highlights Impact of COVID-19 Pandemic on Cancer Screening Delays
Investigators have found further evidence to quantify the vast, lingering impact of the global COVID-19 pandemic on timely cancer screening—highlighting the urgent need for health-care providers to address significant delays to cancer screenings in populations most likely to delay testing,...
Higher Rate of Clonal Hematopoiesis in Pediatric Cancer Survivors May Be Linked With Treatment-Induced STAT3 Gene Mutations and Risk of Adverse Long-Term Outcomes
Studies show that although clonal hematopoiesis is an age-related phenomenon in the general population, it can also be induced by exposure to chemotherapy, which can affect both the emergence and evolution of clonal hematopoiesis clones, accelerating aging at both the physiologic and molecular...
Carl H. June, MD, Honored With 2023 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) will award Carl H. June, MD, with the 2023 AACR Award for Lifetime Achievement in Cancer Research during the AACR Annual Meeting 2023, taking place from April 14 to 19 in Orlando, Florida. Dr. June is the Richard W. Vague Professor in...
Methotrexate May Be Associated With an Increased Risk for Some Skin Cancers
Methotrexate may be linked to an elevated risk of three types of skin cancer, according to a new study published by Polesie et al in the British Journal of Cancer. Additionally, among patients taking the drug to treat moderate to severe psoriasis, an increased risk was observed only for basal cell...
Lung Cancer Screening May Be More Cost-Effective When Using Risk Model–Based Strategies
Risk model–based lung cancer screening strategies may be more cost-effective than current recommendations that are based solely on the patient’s age and smoking history, according to a new study published by Toumazis et al in the Annals of Internal Medicine. The findings also suggested that...
Oncologists Look for Strong Health-Care Priorities in the State of the Union Address
In anticipation of President Joseph R. Biden’s State of the Union Address tonight, ASCO is urging the president to keep cancer care and research as top national priorities. Oncologists have seen how clinical research has improved prevention, detection, and treatment for millions of Americans and...
Expert Point of View: Imane H. El Dika, MD
The sessions’ invited discussant, Imane H. El Dika, MD, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, New York, said the results of the two trials in advanced biliary tract cancer were clear, and did not change the current standard of care of durvalumab combined with...
What Can Be Learned From Negative Findings of Two Trials in Biliary Tract Cancer
Biliary tract cancer is particularly difficult to treat, with a median overall survival of about 1 year with standard-of-care gemcitabine-based regimens. Advanced biliary tract cancer is an area of significant unmet need because of its aggressive nature, limited treatment options, and poor...
SBRT for Patients With Primary Lung Neuroendocrine Tumors
Researchers have found that stereotactic body radiotherapy (SBRT) may be an effective treatment for patients with early-stage lung neuroendocrine tumors, according to a new study published by Oliver et al in the International Journal of Radiation Oncology • Biology • Physics. Background Primary...
Defensive Beliefs May Prevent Individuals From Partaking in Screening for Colorectal Cancer
Investigators have revealed that individuals who react defensively to an invitation for colorectal cancer screening may be less likely to take part, according to a new study published by Clarke et al in Cancer. Background Colorectal cancer is one of the most treatable cancer types—especially if...
Researchers Uncover Racial and Ethnic Disparities in Widely Used Precision Oncology Data Registry
Biorepositories created to support precision cancer research through their vast stores of genomic data may lack sufficient representation of cancer distribution among racial and ethnic minorities, according to a new study published by Cheung et al in npj Precision Oncology. The investigators also...
Preclinical Study Shows Losartan May Prevent Immune Checkpoint Inhibitor–Induced Cerebral Edema in Glioblastoma
Researchers revealed that the blood pressure drug losartan may prevent immunotherapy-induced edema and allow patients with glioblastoma to continue receiving immune checkpoint inhibitors without developing adverse effects in the brain, according to a new study published by Datta et al in...
WHO Launches New Roadmap on Breast Cancer
The World Health Organization (WHO) has released a new Global Breast Cancer Initiative Framework, providing a roadmap to attain targets to save 2.5 million lives from breast cancer by 2040. The new framework recommends that countries implement three pillars of health promotion—early detection,...
Massage Therapy May Improve Symptom Burden for Pediatric Patients With Hematologic and/or Oncologic Conditions
A new study from University Hospitals (UH) Connor Whole Health found children, adolescents, and young adults with cancer or sickle cell disease treated at a pediatric academic medical center reported clinically significant reductions in pain, stress, and anxiety in response to massage therapy....
Researchers Develop AI Algorithm to Gain New Insights Into Glioblastoma
Researchers have developed an artificial intelligence (AI) algorithm, known as SPHINKS, capable of performing advanced computational analyses to identify potential therapeutic targets for patients with glioblastoma multiforme. The platform may also have applicability in other cancers, according to...
OCRA Issues Consensus Statement Calling for Consideration of Fallopian Tube Removal to Prevent Ovarian Cancer
The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) has shown that general population screening did not significantly reduce ovarian and tubal cancer deaths, and the researchers concluded that such screening cannot be recommended. The findings from the study prompted the Ovarian Cancer ...
Review Provides Recommendations on Cancer Treatment in the Context of Preexisting Dementia
According to a review published by Ashley et al in CA: A Cancer Journal for Clinicians, preexisting dementia may complicate cancer care and increase the risk of worse clinical outcome and inferior patient experience. People living with dementia are more likely to have cancer diagnosed at an...
Neoadjuvant Plus Adjuvant Chemotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Colon Cancer
As reported in the Journal of Clinical Oncology by Morton et al, the European phase III FOxTROT trial has shown that neoadjuvant plus adjuvant oxaliplatin/fluoropyrimidine resulted in a reduced risk of residual disease or disease recurrence vs adjuvant oxaliplatin/fluoropyrimidine in patients with...
Study Finds Breast MRI Superior vs Other Supplementary Screening Tests for Detecting Breast Cancer in Patients With Dense Breasts
Compared to other common supplemental screening methods, breast magnetic resonance imaging (MRI) was superior at detecting breast cancer in patients with dense breasts, according to a new study published by Hussein et al in Radiology. Background Breast cancer is one of the leading causes of cancer...
Genomic Screening May Help Detect Medullary Thyroid Cancer, Study Finds
Population-based genomic screening may facilitate early detection of medullary thyroid cancer in patients with variants in the RET gene, according to a new study published by Pichardo et al in JAMA Otolaryngology–Head & Neck Surgery. Background Medullary thyroid cancer accounts for 2% to 5% of...
Momelotinib May Effectively Reduce Anemia and Other Symptoms for Patients With Myelofibrosis
The targeted therapy momelotinib may offer clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, for patients with myelofibrosis, according to a novel study published by Srdan Verstovsek, MD, PhD, and colleagues in The Lancet. The findings support...
New Analysis Sheds Light on Potential Link Between Ovulation and Ovarian Cancer
Individuals who ovulate for longer over their lifetimes may have a higher risk of developing ovarian cancer, suggesting that suppressing ovulation can lower this risk, according to a new study published by Fu et al in the Journal of the National Cancer Institute. The researchers also offered clues...
ctDNA Analysis May Predict Optimal Treatment for Patients With GIST
Circulating tumor DNA (ctDNA) analysis of KIT exon mutations may help predict which second-line therapy is best for patients with advanced gastrointestinal stromal tumor (GIST), according to data presented by Bauer et al during the January ASCO Plenary Series session (Abstract 397784). An...
Analysis of Mutations Associated With High Tumor Mutation Burden in Microsatellite-Stable Gastrointestinal Cancers
In a study reported in The Lancet Oncology, Wang et al identified mutations linked to high tumor mutation burden in microsatellite-stable (MSS) gastrointestinal cancers that may be associated with efficacy of immune checkpoint inhibitor therapy. Study Details Molecular alterations in 48,606...
Receiving Chemotherapy in the Afternoon May Improve Treatment Outcomes in Some Patients With DLBCL
Utilizing chronochemotherapy—a method aimed at delivering chemotherapy at a time when the body is least vulnerable to its harmful effects and when the cancer cells are at their most vulnerable—may improve the outcomes of some patients with diffuse large B-cell lymphoma (DLBCL), according to a novel ...
Undaunted
Soon after my marriage, in 2003, I noticed swelling in the glands around my throat. Although I otherwise felt fine, I went to see my primary care physician for a checkup and a blood test. The results of the test showed that I had an abnormally high number of lymphocytes circulating in my...
Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care
Most of us have felt our stomachs sink as we opened a patient’s radiology or laboratory report and realized the patient faced a grave situation. If we’re lucky, we have a couple of days before a scheduled patient appointment to prepare ourselves to deliver that bad news. Other times, we may have...
Inaugural Recipients of the Lubin Family Foundation Scholar Award Named
The four inaugural recipients of the Lubin Family Foundation Scholar Award have been announced by Dana-Farber Cancer Institute and the Richard K. Lubin Family Foundation. Lubin Scholars are among the most promising physician-scientists pursuing cancer-relevant basic or translational...
Remembering Breast Cancer Pioneer Isaac Craig Henderson, MD
Isaac Craig Henderson, MD, passed away at the age of 81 at his home in San Francisco on December 26, 2022, after a brief illness. Dr. Henderson was an internationally known medical oncologist who specialized in breast cancer, beginning his career at Harvard’s then-designated Sidney Farber Cancer...
Expert Point of View: Nancy Chan, MD
Nancy Chan, MD, Director of Breast Cancer Clinical Research at NYU Langone’s Perlmutter Cancer Center, New York, commented on the monarchE analysis for The ASCO Post. She noted that the study investigated the addition of adjuvant abemaciclib (an oral CDK4/6 inhibitor) to endocrine therapy in a...
Update From monarchE: Benefit of Abemaciclib Increases Over Time in Early-Stage Breast Cancer
Results of a planned interim overall survival analysis of the phase III monarchE trial offered further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk disease, according to Stephen R.D....
Intensive Remission Induction Chemotherapy vs Less Intensive Approach Prior to Transplant for Relapsed/Refractory AML
Intensive salvage therapy with the goal of achieving complete remission prior to allogeneic hematopoietic cell transplantation (alloHCT) may not be necessary in some patients with relapsed or refractory acute myeloid leukemia (AML), according to the results of the phase III ASAP trial presented at...
KU Medical Center Researchers Receive R01 Grant From NCI to Improve Access to Targeted Cancer Treatments for Rural Patients
Precision medicine has revolutionized cancer treatment—but only for patients who have access to treatments. Nearly 2 million people in the United States are diagnosed each year with cancer, but access to targeted treatments varies widely, and only about half of the eligible people receive them,...
The Influence of Structural Racism and Poverty on Outcomes in Leukemia
In the United States, Black American patients with acute myeloid leukemia (AML) have notably worse survival outcomes compared to White patients. In addition, Black patients are less likely to receive intensive chemotherapy and undergo allogeneic stem cell transplants. Many researchers have reported ...
Northwell Receives Gift From Trustee Roy J. Zuckerberg to Create First Cancer Hospital and Cancer Campus on Long Island
Northwell Health recently announced a gift from longtime trustee Roy J. Zuckerberg to create the R.J. Zuckerberg Cancer Hospital at Long Island Jewish (LIJ) Medical Center—Long Island’s first cancer hospital—and to establish the R.J. Zuckerberg Cancer Center, Northwell’s largest ambulatory cancer...
How Experts Treat Mantle Cell Lymphoma in First Complete Response
Options are growing in the treatment of mantle cell lymphoma after complete response. At the 2022 Pan Pacific Lymphoma Conference,1 the use of these newer strategies in older patients was discussed by Brad S. Kahl, MD, Professor of Medicine and Director of the Lymphoma Service at Washington...
Being on the Other Side: An Oncologist’s Perspective on Grieving
As an oncologist, I had cared for patients facing grave illness and death. I imagined the loss of loved ones and expected grief to be an unbearable sadness, most poignant in the earliest days and lessening with time. I somehow expected that counseling people who grieved would make me more prepared. ...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
Cardiovascular Events Before and After Initiation of Immune Checkpoint Inhibitor Therapy for Cancer
In a study reported in JACC: CardioOncology, Lavanya Kondapalli, MD, of the University of Colorado School of Medicine, Aurora, and colleagues found that cardiovascular events common in the general population were observed both prior to and after the initiation of immune checkpoint inhibitor therapy ...
Study Explores the Addition of First-Line Atezolizumab in BRAF V600–Mutant Advanced Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but...
FDA Oncology Center of Excellence Seeks Applications for New Research Funding Opportunities
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Julie A. Schneider, PhD, Associate Director for Research Strategy and Partnerships, OCE; Jennifer J. Gao, MD,...
New Study Evaluates Online Colorectal Cancer Risk Calculators
Many individuals considering screening for colorectal cancer may want information on their personal risk when making decisions about screening—such as whether to select an at-home stool-based test or colonoscopy. Investigators evaluated five online colorectal cancer risk calculators to determine...
Trends in Stage, Treatment, and Outcomes in Rectal Adenocarcinoma in the United States: 2004 to 2019
In a retrospective, observational case series study reported in JAMA Oncology, Emile et al identified changes in the stage at diagnosis, treatments, and outcomes in U.S. patients with rectal adenocarcinoma diagnosed between 2004 and 2019. Study Details The study used National Cancer Database data...
NAPOLI-3: First-Line NALIRIFOX Regimen Improves Overall Survival in Metastatic Pancreatic Cancer
In the phase III NAPOLI-3 trial in previously untreated patients with metastatic pancreatic cancer, the NALIRIFOX regimen significantly improved overall survival and progression-free survival over nab-paclitaxel plus gemcitabine. NALIRIFOX contains liposomal irinotecan, fluorouracil, leucovorin,...
ASCO Guideline Offers Recommendations on Prescribing Opioids to Patients With Cancer
A new ASCO guideline on opioids in managing pain from cancer or cancer treatment in adults provides recommendations on administering them in the midst of interventions to address the public health crisis from their misuse and related deaths across the country.1 “ASCO took wonderful leadership in...
Expert Point of View: Solange Peters, MD, PhD
The formal discussant of ARC-7 was Solange Peters, MD, PhD, Chair of Medical Oncology, Centre D’Oncologie Chuv, Lausanne University Hospital, Switzerland, and President of the European Society for Medical Oncology. Dr. Peters described how TIGIT (T-cell immunoglobulin and ITIM domain) plays a role ...
Anti-TIGIT Antibody May Boost the Benefit of Immunotherapy in Stage IV Lung Cancer
In a phase II study of stage IV non–small cell lung cancer (NSCLC), domvanalimab, a novel antibody that blocks T-cell immunoglobulin and ITIM domain (TIGIT), when added to anti–PD-1 zimberelimab immunotherapy resulted in improved response rates and progression-free survival compared with...
Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia With a Susceptible IDH1 Mutation
On December 1, 2022, the IDH1 inhibitor olutasidenib was approved for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1 The FDA simultaneously approved the Abbott...
Expert Point of View: Jane N. Winter, MD and Catherine Bollard, MBChB, MD
Offering their thoughts on the study by Williams et al from the St. Jude Lifetime Cohort were Jane N. Winter, MD, Immediate Past President of the American Society of Hematology (ASH), and Catherine Bollard, MBChB, MD. Both moderated press briefings where the results were presented or discussed....
Many Survivors of Childhood Hodgkin Lymphoma Show Signs of Neurocognitive Impairment
Long-term follow-up of survivors of childhood Hodgkin lymphoma from the St. Jude Lifetime Cohort showed signs of “epigenetic accelerated aging,” and many of these survivors had signs of neurocognitive impairment by their late 30s, researchers reported at the 2022 American Society of Hematology...
